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724Incidence and Risk of Postherpetic Neuralgia after
Varicella Zoster Virus Infection in Hematopoietic Cell
Transplantation Recipients: Hokkaido Hematology
Study Group
Masahiro Onozawa,1 Satoshi Hashino,1 Yoshifumi Haseyama,2 Yasuo Hirayama,3
Susumu Iizuka,4 Tadao Ishida,5 Makoto Kaneda,6 Hajime Kobayashi,7 Ryoji Kobayashi,8
Kyuhei Koda,9 Mitsutoshi Kurosawa,10 Nobuo Masauji,11 Takuya Matsunaga,12 Akio Mori,13
Masaya Mukai,14 Mitsufumi Nishio,1 Satoshi Noto,15 Shuichi Ota,16 Hajime Sakai,17
Nobuhiro Suzuki,18 Tohru Takahashi,19 Junji Tanaka,1 Yoshihiro Torimoto,20
Makoto Yoshida,21 Takashi Fukuhara22To assess the incidence of and risk factors associated with postherpetic neuralgia (PHN) after hematopoietic
cell transplantation (HCT) varicella zoster virus (VZV) infection, we conducted a retrospective chart review
of 418 consecutive patients who underwent HCT between April 2005 and March 2007. The male/female ra-
tio was 221/197, median age at HCTwas 47 years (range: 0-69 years), and autologous/allogeneic/syngeneic
HCTratio was 154/263/1. Seventy-eight patients developed VZV infection after HCT. Sixty-two patients had
localized zoster, 11 patients had disseminated zoster (rash like chicken pox), and 4 patients had visceral zos-
ter. All cases were treated with acyclovir (ACV) or valacyclovir (VACV), and there was no VZV infection-
related death. Twenty-seven (35%) of the 78 patients with VZV infection suffered PHN after resolution of
VZV infection. Multivariate analysis showed that advanced age is the only risk factor in autologous HCT
(P 5 .0075; odds ratio [OR] 5 1.14; 95% confidence interval [CI], 0.97-1.33). On the other hand, advanced
age (P5.0097; OR5 1.06; 95% CI, 1.01-1.12), male gender (P5.0055; OR5 12.7; 95% CI, 1.61-100.1), and
graft-versus-host disease (GVHD) prophylaxis with a tacrolimus-based regimen (P5 .0092; OR5 9.56; 95%
CI, 1.44-63.3) were associated with increased risk of PHN in allogeneic HCT. This study for the first time
clarified the risk of PHN in HCT recipients.
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Biol Blood Marrow Transplant 15:724-729, 2009 725PHN after VZV Infection in HCT RecipientsINTRODUCTION Table 1. Patients’ Characteristics.Male/Female: 221/197
Age (Median): 0-69/(47)
VZV Infection (+)/(-): 78/340
Hemotologica Disease:
Acute Myelogenous leukemia 93
Acute Lymphoblastic leukemia 48
Myelodysplastic syndrome 30
Chronic myelogenous leukemia 10
Non-Hodgkin lymphoma 115
Severe aplastic anemia 14
Hodgkin lymphoma 10
Multiple myeloma 46
Plasma cell dyscrasia 8
Congenital disease 7
Solid tumor 17
Adult T cell leukemia 5
Secreloderma 5
Myeloproliferative disease 5
Juvenile myelomonocytic leukemia 3
Chronic lymphocytic leukemia 1
Chronic neutrophilic leukemia 1Reactivation of varicella zoster virus (VZV) is
a common event in patients undergoing hematopoietic
cell transplantation (HCT) [1-5]. In HCT recipients,
VZV reactivation frequently occurs as localized zoster
and sometimes as disseminated cutaneous lesions re-
sembling varicella with or without visceral involve-
ment, which results in a high mortality rate. The
most common complication associated with zoster in
healthy individuals is chronic and often debilitating
pain called postherpetic neuralgia (PHN), which can
last for several yeas and may reduce quality of life. Al-
though many previous studies have shown a high inci-
dence of VZV reactivation after HCT, the incidence
and risk of PHN in HCT recipients have not yet
been clarified.Stem cell source:
auto PBSCT 154
allogeneic 263
related BMT 38
related PBSCT 55
related CBT 2
unrelated BMT 95
unrelated CBT 73
syngeneic 1
Preparative regimen in allo- HCT
CST/RIST 146/117
PBSCT indicates peripheral blood stem cell transplantation; CST, con-
ventional stem cell transplantation; RIST, reduced intensity stem cell
transplantation; CBT cord blood transplantation; BMT bone marrow
transplantation; HCT, hematopoietic cell transplantation; VZV, varicella
zoster virusPATIENTS AND METHODS
Patients
To assess the incidence and risk factors associated
with PHN after post-HCT VZV infection, we con-
ducted a retrospective chart review of 418 consecutive
patients who underwent HCT in Hokkaido Hematol-
ogy Study Group (HHSG) between April 2005 and
March 2007. HHSG is a multicentric clinical study
group that includes ‘‘all’’ hematology departments in
Hokkaido prefecture, consisting of 26 clinical groups
of 19 institutes. VZV infection was defined by the ap-
pearance of typical cutaneous vesicular lesions or the
detection of the VZV antigen. Information on pre-
transplant therapeutic exposures, HCT procedures,
and posttransplant health complications was obtained
via evaluation form. A total of 418 patients were in-
cluded in this study. Patients characteristics are sum-
marized in Table 1. Male/female ratio was 221/197,
median age at HCT was 47 years (range: 0-69 years),
autologous HCT/allogeneic HCT/syngeneic HCT
ratio was 154/263/1, and median length of follow-
up was 344 days (range: 3-1165 days). Short-term
(up to 6 weeks) administration of acyclovir (ACV) or
valacyclovir (VACV) has been widely used as prophy-
laxis against herpes simplex virus (HSV) in Japan.
Duration of prophylactic ACV or VACV differed in
each institution. The current Japanese medical insur-
ance system only covers oral ACV at 1000 mg/day
from HCT day 27 to day 35 in allogeneic HCT. In
an autologous transplantation setting, duration of
prophylactic antiviral drug administration varied
from 0 to 239 days (median of 7 days), and in an allo-
geneic transplantation setting, duration varied from
10 to 189 days (median of 43 days). Duration of pro-
phylactic antiviral drug administration was longer in
an allogeneic HCT setting than in an autologous
HCT setting (P\ .001).Diagnosis of Clinical VZV Infection
VZV infection was defined by the appearance of
typical cutaneous vesicular lesions or the detection
of VZV antigen. Localized zoster was defined as
the presence of vesicular lesions in a dermatomal
distribution. Disseminated zoster was defined as
a generalized vesicular eruption that is identical to
that of varicella. Visceral dissemination was defined
as clinical evidence of internal organ involvement
in the absence of other identified pathogens that
might have accounted for the clinical syndrome.
PHN was defined as dermatomal pain that persisted
beyond rash healing.
Statistical Analysis
The incidence of VZV reactivation was calculated
by the Kaplan-Meier method, and differences between
groups were compared using the log-rank test. We
performed univariate analysis for comparisons be-
tween different groups of patients or clinical data using
the chi-square test and t-test, as appropriate. We
performed multivariable logistic regression modeling
with the forward stepwise method to assess which
predictors independently contribute to prediction of
PHN and to what extent using odds ratios with 95%
726 Biol Blood Marrow Transplant 15:724-729, 2009M. Onozawa et al.CI. All P-values were 2-sided, and a value of P 5 .05
was used as a cutoff for statistical significance. Patients
who remained free of VZV infection after transplanta-
tion were censored at the time of their last follow-up or
death from unrelated causes. A case with syngeneic
transplantation was dealed with as an autologous
transplantation. Analyses were done with Dr. SPSS
for Windows (version 8.0.1J).RESULTS
VZV Reactivation
Seventy-eight patients developed VZV infection
after HCT (M/F 5 36/42; median age, 48 [range: 3-
68] years; auto/allo/syngeneic 5 29/48/1). Sixty-two
patients had localized zoster (single dermatome in
53, double dermatomes in 9), 12 patients had dissem-
inated zoster (rash like chicken pox), and 4 patients had
visceral zoster (involvement of the gastrointestinal
[GI] tract). No VZV infection occurred during the pe-
riod of prophylactic antiviral drug administration. All
cases were treated with ACV or VACV, and there was
no VZV infection-related death. The incidence of
VZV infection in females (21.3%) was slightly higher
than that in males (16.7%), but the difference was
not statistically significant (P 5 .22). The incidences
of VZV infection were not different between age
groups. After resolution of VZV infection, VZV infec-
tion re-occurred in 5 cases (localized zoster in 4 cases,
and visceral zoster in 1 case). Cumulative incidences of
VZV infecion in allo-HCT and auto-HCT recipients
were estimated to be 34% and 22%, respectively, at 2
years after HCT (log-rank P 5 .23) (Figure 1). In au-
tologous HCT, 96.6% of the cases of VZV infection
occurred during the first year after HCT, but in allo-
geneic HCT, only 75.5% of the cases of VZV infec-
tion occurred during the first year after HCT. The
cumulative incidences of VZV infection in auto-
HCT and allo-HCT recipients were not statistically
different because the incidence curves crossed at 1
year after HCT. However, in an autologous setting,Figure 1. Incidence of VZV infection after HCT (auto versus allo).prophylactic usage of ACV was shorter (0-239 days,
median of 7 days) than that in an allogeneic HCT set-
ting (10-189 days, median of 43 days) (P\ .001). Be-
cause no VZV infection occurred during the period
of prophylactic antiviral drug administration, earlier
onset of VZV infection in auto-HCT recipients may
result from the shorter period of prophylactic antiviral
drug usage. In an allogeneic setting, the rate of VZV
infection in patients who underwent related donor
bone marrow transplantation (rBMT) was lower than
that in patients who underwent transplantations of
stem cells of other sources (Figure 2).
Incidence of PHN
Twenty-seven (35%) of the 78 patients with VZV
infection suffered PHN after resolution of VZV in-
fection (M/F 5 15/12; median age, 56 [range: 21-
64] years; auto/allo 5 13/14). Although incidences
of VZV infection were not different between age
groups, the incidence of PHN increased with advan-
cement of age (Figure 3). Univariate analysis showed
advanced age to be a risk factor in both allogeneic
HCT and autologous HCT (Table 2). In allogeneic
HCT, tacrolimus usage and graft-versus-host disease
(GVHD) at onset of VZV infection were shown to be
risk factors. There was no significant difference be-
tween the incidence of PHN in patients in whom an-
tiviral therapy was initiated within 24 hours of clinical
onset (no Tx delay) and that in patients in whom an-
tiviral therapy was initiated after 24 hours from onset
(Tx delay). Multivariate analysis showed that ad-
vanced age is the only risk factor in autologous
HCT (P 5 .0075; OR 5 1.14; 95% CI, 0.97-1.33).
On the other hand, advanced age (P 5 .0097; OR
5 1.06; 95% CI, 1.01-1.12), male sex (P 5 .0055;
OR 5 12.7; 95% CI, 1.61-100.1), and GVHD
prophylaxis with a tacrolimus-based regimen (P 5
.0092; OR 5 9.56; 95% CI, 1.44-63.3) were associ-
ated with increased risk of PHN in allogeneic
HCT. Results of statistical analysis between autolo-
gous versus allogeneic HCT (data not shown), onset
of VZV infection after HCT, gammaglobulin usage,Figure 2. Incidence of VZV infection after HCT (stem cell source).
Figure 3. (A) Incidence of VZV infection after HCT. (B) Incidence of PHN after VZV infection.
Biol Blood Marrow Transplant 15:724-729, 2009 727PHN after VZV Infection in HCT Recipientslocalization of rash, conventional stem cell transplan-
tation (SCT) versus reduced-intensity stem cell trans-
plantation (RIST), stem cell source, and GVHD at
onset of VZV infection were not significant.DISCUSSION
Herpes Zoster after HCT
Reactivation of latent VZV, presenting as local-
ized zoster or as disseminated infection, is a common
and potentially serious complication in HCT recipi-
ents. Previous studies revealed that 23% to 60% of
patients could be expected to develop VZV infection
after HCT [1-4]. Analyses of risk factors such as allo-
geneic versus autologous transplant, GVHD, under-
lying disease, and pre-BMT irradiation have not
revealed definitive associations [1,2]. In our study,
age, sex, SCT versus RIST, and total body irradiation
(TBI) did not show a definitive association with VZV
infection after HCT. Tomonari et al. [6] reported
a high risk of VZV infection after cord blood trans-
plantation (CBT). In our series, CBT has a similar
risk of VZV infection similar to that of other stem
cell sources except related bone marrow, which
showed a lower risk.
Cutaneous and Visceral Dissemination
VZV infection after HCT sometimes progressed
to systemic infection. In previous series, 2% to 20%
of the cases of VZV infection were disseminated zos-
ter, and 3% to 5% of cases were visceral dissemina-
tion such as acute abdomen, pneumonitis, and
central nervous system (CNS) involvement [1]. Risk
of disseminated disease has not been studied in detail.
Previously, we showed an association of preexisting
(before onset of VZV infection) anti-VZV IgG titerand disseminated VZV infection [5]. In our previous
observations, herpes zoster occurred despite pro-
longed existence of anti-VZV IgG after HCT. Recip-
ients with lower preexisting VZV-IgG titer had
higher viral copies in their serum at onset of VZV in-
fection and tended to present as a disseminated dis-
ease. It is well known that cell-mediated immunity
to VZV is a major determinant of the risk and sever-
ity of herpes zoster; however, decreasing humoral im-
munity after HCT might contribute to disseminated
VZV infection.
Second Episodes of Herpes Zoster
Five patients (one autologous HCT recipient, 4
allogeneic HCT recipients) developed 2 episodes of
VZV infection after HCT. The average interval be-
tween episodes was 9 months (range: 2-31 months).
Four recipients had recurrence as localized zoster
and 1 recipient had recurrence as visceral zoster
(esophageal involvement). Two of the 5 patients
with multiple VZV infections suffered PHN. In im-
munocompetent individuals, a second episode after
resolution of zoster is quite unusual, but HCT recip-
ients sometimes have plural episodes of VZV infec-
tion, indicating the failure to reconstitute VZV
specific immunity because of prolonged insufficient
immunity [1].
PHN
PHN is the most common complication of her-
pes zoster in immunocompetent as well as immuno-
compromised patients. Many patients develop severe
physical and social disabilities as a consequence of
their unceasing pain. Because the effect of treatment
is disappointing once the syndrome has occurred,
the importance of PHN-preventive strategies is
widely recognized. HCT recipients apparently
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728 Biol Blood Marrow Transplant 15:724-729, 2009M. Onozawa et al.seem to be at higher risk of PHN. Locksley et al. [7]
observed PHN in 25% of HCT recipients, a much
higher incidence than the expected incidence of
about 9% in healthy individuals. Koc et al. [8]
reported that PHN and peripheral neuropathy
occurred in 43% of HCT recipients. There has been
no report in which prevalence and precise risk of
PHN after VZV infection in HCT recipients was
described. Previous studies in immunocompetent
individuals showed that advanced age, acute pain se-
verity, presence of severe rash, rash duration before
consultation, greater degree of sensory impairment,
ophthalmic location, and psychologic distress were
potential predictors of PHN [9,10]. Advanced age
is the strongest risk factor in immunocompetent
adults [11]. The incidence of PHN was reported to
be much higher in immunocompetent patients over
60 years old [11]. In HCT recipients, the incidence
of PHN was higher at a younger age than that in
healthy individuals. This study for the first time clar-
ified the risk of PHN in HCT recipients. The inci-
dence of PHN in HCT patients of a younger age
(age . 20 years) was higher than that in healthy indi-
viduals. Previous observations support the belief that
a decline in cell-mediated immunity to VZV can lead
to a higher incidence and greater severity of herpes
zoster and PHN [12]. Because of severe cellular im-
munoincompetence, the risk of PHN is considered
to be high in HCT recipients. In our series, the in-
cidences of VZV infection were not significantly dif-
ferent in males and females, but the incidence of
PHN was higher in males only in allogeneic HCT
recipients. The effect of sex on risk of herpes zoster
or PHN is controversial [11].Prophylaxis
In our series, immediate antiviral drug administra-
tion did not reduce the incidence of PHN. A previous
study in immunocompetent individuals showed that
antiviral therapy reduced the severity and duration of
herpes zoster, but did not prevent the development of
PHN [13]. One factor potentially limiting the effect
of antiviral agents on chronic pain is the fact that
VZVreplication occurs for several days orweeks before
a rash appears and a diagnosis can be made. Therefore,
to prevent PHN, we should prevent VZV reactivation
itself. Some studies have shown successful long-term
usage of ACV for prophylaxis of VZV infection after
HCT. Administration of ACV for a period as long as
that immunosuppressant usage and at least 1 year after
HCT even at a low dose (ACV 200-400 mg daily) suc-
cessfully reduced the incidence of VZV reactivation at
1 year afterHCT, but VZV reactivation after cessation
of ACV administration was still high (29%-32.1%)
[14,15]. Another study showed that subclinical reacti-
vation was important to reconstitute donor-derived
Biol Blood Marrow Transplant 15:724-729, 2009 729PHN after VZV Infection in HCT RecipientsVZV-specific immunity [16]. It has been shown that
in vivo reexposure to VZV antigens without clinical
symptoms may boost immunity and thereby pre-
vent subsequent symptomatic VZV reactivation [16].
Therefore, administration of ACV suppresses VZV
reactivation, but at the same time might also suppress
recovery ofVZV-specific immunity by preventing con-
tact of immune cells with the VZV antigen. Active im-
munization by a vaccine is theoretically reasonable;
however, the current VZV vaccine used worldwide is
a live attenuated vaccine, and, therefore, cannot be
used inHCT recipients for a periodwithin 2 years after
transplantation [17]. Inactivated varicella vaccine may
be useful for the early reconstitution of adaptive immu-
nity to VZV after HCT [1,18]. A live attenuated vac-
cine does not work during antiviral drug usage, but
inactivated vaccine can be administered during pro-
phylactic antiviral drug usage. Therefore, 1 possible
approach is to administer an inactivated VZV vaccine
before the discontinuation of prophylactic antiviral
drug administration. Appropriate duration of adminis-
tration and dose of a prophylactic antiviral drug and
appropriate timing of inactivatedVZV vaccine admini-
stration must be studied prospectively.ACKNOWLEDGMENTS
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